{
    "ticker": "PHASQ",
    "name": "PhaseBio Pharmaceuticals, Inc.",
    "description": "PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for rare and specialty diseases. Founded in 2012 and headquartered in Malvern, Pennsylvania, PhaseBio focuses on developing novel biologic therapies that address significant unmet medical needs. Its lead product candidate, PB2452, is an investigational therapy designed to reverse the effects of antiplatelet drugs such as ticagrelor, providing a critical solution in emergency settings where rapid reversal is needed. The company employs its proprietary technology platform, which includes its unique fusion protein technology, to create next-generation therapies with enhanced efficacy and safety profiles. With a strong emphasis on research and development, PhaseBio is committed to bringing transformative treatments to patients while collaborating with healthcare professionals and industry partners to optimize patient outcomes. The company is focused on expanding its pipeline and has several other candidates under investigation for various indications, showcasing its commitment to innovation in the biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Malvern, Pennsylvania, USA",
    "founded": "2012",
    "website": "https://www.phasebio.com",
    "ceo": "John W. R. B. G. McKenzie",
    "social_media": {
        "twitter": "https://twitter.com/PhaseBio",
        "linkedin": "https://www.linkedin.com/company/phasebio-pharmaceuticals/"
    },
    "investor_relations": "https://investors.phasebio.com",
    "key_executives": [
        {
            "name": "John W. R. B. G. McKenzie",
            "position": "CEO"
        },
        {
            "name": "Robert W. G. McKenzie",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PB2452"
            ]
        }
    ],
    "seo": {
        "meta_title": "PhaseBio Pharmaceuticals, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore PhaseBio Pharmaceuticals, Inc., a leader in developing innovative therapies for rare diseases, including PB2452 for antiplatelet drug reversal.",
        "keywords": [
            "PhaseBio",
            "Biopharmaceuticals",
            "Rare Diseases",
            "PB2452",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is PhaseBio Pharmaceuticals known for?",
            "answer": "PhaseBio Pharmaceuticals is known for developing innovative therapies for rare and specialty diseases, particularly PB2452 for antiplatelet drug reversal."
        },
        {
            "question": "Who is the CEO of PhaseBio Pharmaceuticals?",
            "answer": "John W. R. B. G. McKenzie is the CEO of PhaseBio Pharmaceuticals, Inc."
        },
        {
            "question": "Where is PhaseBio headquartered?",
            "answer": "PhaseBio is headquartered in Malvern, Pennsylvania, USA."
        },
        {
            "question": "What are PhaseBio's main products?",
            "answer": "PhaseBio's main product candidate is PB2452, which is in clinical development for the reversal of antiplatelet therapy."
        },
        {
            "question": "When was PhaseBio founded?",
            "answer": "PhaseBio was founded in 2012."
        }
    ],
    "competitors": [
        "NVS",
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "GILD",
        "ABBV"
    ]
}